Previous studies (7, 8) have identified FGF21 as a novel biomarker with significant diagnostic and prognostic value in cardiovascular diseases, diabetes, and non-alcoholic fatty liver disease (NAFLD). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.